AHOD1822 -- AnOpen-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)

Grant

Date/time Interval

  • April 13, 2020 - April 12, 2026
  • Total Award Amount

  • 216974.00
  • Direct Costs

  • 159540.00
  • Sponsor Award Id

  • Contributor

  • Aman Wadhwa   Investigator  
  • Amitkumar Mehta M.D.   Investigator  
  • Ana Galtarossa Xavier   Principal Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Matthew Kutny M.D.   Investigator  
  • Wayne Liang   Investigator